What is Pherecydes Pharma?
Pherecydes Pharma operates as a specialized entity within the life sciences sector, focusing on the development of innovative therapeutic solutions. The company's market position is defined by its ability to attract high-caliber venture capital, which serves as a testament to its technical rigor and strategic vision. By leveraging its recent capital influx, the organization is well-positioned to accelerate its research and development pipelines, effectively bridging the gap between laboratory innovation and commercial application. The firm remains a key player for stakeholders interested in the intersection of biotechnology and high-growth enterprise development.
How much funding has Pherecydes Pharma raised?
Pherecydes Pharma has raised a total of $15.5M across 3 funding rounds:
Series A
$2.3M
Unspecified
$2.9M
Series B
$10.3M
Series A (2014): $2.3M with participation from Auriga Partners
Unspecified (2015): $2.9M, investors not publicly disclosed
Series B (2018): $10.3M supported by Go Capital, Auriga Partners, Omnes Capital, and Fa-Dièse
Key Investors in Pherecydes Pharma
Go Capital
A China-Israel fund specializing in high-tech sectors including life sciences, cyber security, and artificial intelligence, focused on facilitating market penetration into China.
Omnes Capital
A prominent European private equity firm managing over 6.7 billion euros, with a strong emphasis on energy transition, deeptech innovation, and sustainable growth.
Fa-Dièse
A Paris-based micro VC fund that combines the agility of business angels with the structured approach of venture capital to support early-stage startups in digital and life sciences.
What's next for Pherecydes Pharma?
Looking ahead, the strategic deployment of $10.3M will likely focus on scaling operational capacity and expanding market reach. With the support of seasoned institutional backers, Pherecydes Pharma is poised to navigate the complexities of the regulatory and commercial landscape. The focus will remain on executing key milestones that drive value creation, ensuring that the firm maintains its competitive edge while continuing to attract interest from global investors. Future growth will be contingent upon the successful translation of its research initiatives into tangible market outcomes, supported by the firm's established network of strategic partners.
See full Pherecydes Pharma company page
